Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Full-year 2025 earnings release issued Feb 26, 2026: financial details in Exhibit 99.1.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 earnings release issued Feb 26, 2026: financial details in Exhibit 99.1
- Covers fiscal year ended Dec 31, 2025: annual results, not a quarterly update
Item 7.01 · Regulation FD Disclosure
- Indivior posted investor presentation materials (Exhibit 99.2) and updated corporate presentation (Exhibit 99.3) to its website on Feb 26, 2026
- Reg FD disclosure ensures simultaneous public access: content likely includes strategy, pipeline, or financial guidance relevant to institutional investors
- Full substance in Exhibits 99.2 and 99.3; review those directly for actionable detail
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.